Practice Resources

GLP-1 Receptor Agonists

GLP1 Resources

People with type 2 diabetes do not make enough of the hormone glucagon-like peptide (GLP-1) receptor agonists, which are released from the intestines after eating to reduce blood glucose levels, among other things. Manmade GLP-1 medications replace this lost hormone and have amplified effects including improved glucose levels, better weight management and even decreased risk of heart attacks and stroke. This class of drugs can be an especially effective tool in managing hyperglycemia in adults with type 2 diabetes.

What are GLP-1 medications?

 

 

Tip Sheets

Understanding GLP-1 Receptor Agonists

Understanding GLP-1 Receptor Agonists

Also available in Spanish/Español.

Using GLP-1 Receptor Agonists

Using GLP-1 Receptor Agonists

Also available in Spanish/Español.

 

 
 


 

Journal Articles 

AADE in Practice coverAADE in Practice

Beyond Insulin: Novel Approaches to Treating Type 1 Diabetes
Geoffrey Twigg, PHARMD, BCACP, CDE, Benjamin Forrest, PHARMD, Lana Saad Sherr, PHARMD, BS PHARM, Haroon Amir, PHARMD CANDIDATE
First Published February 13, 2019

Managing Diabetes by Maintaining Healthier Beta Cells: A Fresh Perspective for DiabetesCare and Education Specialists
Gary Scheiner, MS, CDE, Stanley S. Schwartz, MD, FACP, FACE, Mary E. Herman, PhD
First Published June 25, 2018

Managing Adverse Effects Related to Newer Type 2 Diabetes Medications
Oluwaranti Akiyode, PharmD, BCPS, CDE
First Published October 19, 2015.

Glucagon-Like Peptide Receptor Agonists: A Viable Addition to Basal-Bolus Therapy in Type 2 Diabetes?
Tommy Johnson, PharmD, CDE, BC-ADM, FAADE, Tiffaney Threatt, PharmD, CDE, Sarah Wagner, PharmD,Eileen Ward, PharmD, BCACP
First Published December 18, 2014.

The Diabetes EducatorThe Diabetes Educator Cover

Understanding GLP-1 Analogs and Enhancing Patient Success
Vol. 36, 3-suppl: pp. 44S-72S. First Published August 24, 2010
Davida F. Kruger, MSN, APN-BC, BC-ADM, Bruce Bode, MD, FACE, Geralyn R. Spollett, MSN, ANP-CS, CDE

GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice
Vol. 41, 1-suppl: pp. 32S-46S. First Published October 8, 2015
Curtis Triplitt, PharmD, CDE; Carolina Solis-Herrera, MD

Complementary Approaches to Improving Glucose Control—Insulin and Incretins: Patient Case Studies in Action

Vol. 40, 1_suppl: pp. 4S-26S. First Published May 19, 2014
Jerry Meece, RPh, FACA, CDE, FAADE, Teresa L. Pearson, MS, RN, CDE, FAADE, Linda M. Siminerio,RN, PhD, CDE, FAAN

In This Section

Practice